Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant. (October 2019)

• Record Type: Journal Article
• Authors: Bazarbachi, Abdul Hamid; Al Hamed, Rama; Malard, Florent; Mohty, Mohamad; Bazarbachi, Ali
• Is Part Of: Therapeutic advances in hematology. Volume 10(2019)
• Publication Date: 2019-10
• Subjects: Acute Myeloid Leukemia -- Allogeneic Transplantation -- FLT3 -- Miostaurin -- Sorafenib -- Quizartinib -- Gilteritinib; Hematology -- Periodicals; Hematologic Diseases -- therapy -- Periodicals; Hematology -- Periodicals; 616.15005
• DOI: 10.1177/2040620719882666
• Languages: English
• ISSNs: 2040-6207

Abstract

FMS-like tyrosine kinase 3 ( FLT3 ) mutations are one of the most frequently encountered genetic alterations in acute myeloid leukemia (AML), and are generally associated with unfavorable outcomes. Several tools are currently available to provide an accurate prognosis for patients with these mutations, including FLT3 mutation type (internal tandem duplication versus tyrosine kinase domain), mutation allelic ratio (high versus low), and concurrent nucleophosmin-1 ( NPM1 ) mutation, to help decide on optimal treatment. Recent advances in targeted therapies have paved the way for modern treatment strategies, such as the development of FLT3 kinase inhibitors. These novel drugs can be incorporated into any treatment component, including induction and consolidation, the relapse/refractory setting, bridging for transplant, salvage post-transplant, and as prophylactic long-term post-transplant maintenance. Many challenges remain though, such as their intolerability with high-dose chemotherapy in frail patients; whether their optimal use involves watchful waiting for molecular or hematologic relapse compared with prophylactic use as maintenance; and the exact role and indication for allogeneic stem cell transplantation, which arguably remains the only curative option for these high-risk patients.